**Right Care Heart Disease, Stroke and Diabetes Prevention and Management Continuing Medical Education (On-Demand & Complementary)**

**Hypertension Part 1: Practical Tips & Tactics. Right Care Heart Attack & Stroke Prevention (2.10.25).**

February 26, 2025 – December 31, 2027

**Purpose**

This lecture provides an overview of suggested tools, tactics and topics to be used with clinicians and patients to improve blood pressure control rates across a health-system population of patients with a diagnosis of hypertension. The live lecture for this recording took place February 10, 2025.

Presented by Scott Flinn, MD & Cindy Giambrone, PharmD.

**Target Audience**

Specialties – Emergency Medicine, Family Medicine, Medicine, Neurology, Obstetrics & Gynecology, Radiological Sciences, Cardiology, General Internal Medicine & Primary Care, Pulmonary Diseases & Critical Care Medicine, Rheumatology

Professions – Physician, Non-Physician, Medical Assistant, Medical Student, Nurse, Nurse Practitioner, Pharmacist, Pharmacy Technician, Physician Assistant, Registered Dietitian, Resident Physician, Social Worker

**Activity Objectives**

1 Quantify the US Patient Population with Hypertension and current diagnosis and control rates

2 Describe Best Clinical Practices to improve hypertension control rates across a health-system population

3 Identify appropriate interventions by pharmacy, medical and other clinical staff to improve hypertension control rates across a health-system population

**Accreditation Statement**

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of California, Irvine School of Medicine and UC Berkeley, Right Care Initiative. The University of California, Irvine School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

**Designation Statement**

The University of California, Irvine School of Medicine designates this Enduring Material for a maximum of 0.50 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**California Assembly Bill 1195 and 241**

This activity is in compliance with California Assembly Bill 1195 and 241, which require CME activities with patient care components to include curriculum in the subjects of cultural and linguistic competency & implicit bias. It is the intent of AB 1195 and AB 241 to encourage physicians and surgeons, CME providers in the State of California, and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population and reduce health disparities through appropriate professional development. Please see the CME website, <https://www.meded.uci.edu/CME/> for AB 1195 and AB 241 resources.









**Faculty & Planner Disclosures**

University of California, Irvine School of Medicine Continuing Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Sarah Epstein, PhD | Other Planning Committee Member | Nothing to disclose - 10/23/2024 |
| Hattie Hanley, Other | Course Director | Nothing to disclose - 10/23/2024 |
| Karen M Sky, MD | Activity Administrator | Nothing to disclose - 10/23/2024 |
| Nathan D. Wong, PhD, MPH | Other Planning Committee Member | Grant or research support-Novartis Corporation Pharmaceuticals|Consulting Fee-Novartis Corporation Pharmaceuticals|Consulting Fee-Amgen, Inc.|Consulting Fee-Ionis Pharmaceuticals|Grant or research support-Novo Nordisk (Any division) (Relationship has ended)|Consulting Fee-Heart Lung|Grant or research support-Amgen, Inc.|Speakers Bureau-Novartis Corporation Pharmaceuticals - 01/06/2025 |
| Jan Hirsch, PhD | Other Planning Committee Member | Nothing to disclose - 10/23/2024 |
| Cindy Giambrone, PharmD | Faculty | Stocks or stock options, excluding diversified mutual funds-Sanofi S.A.|Stocks or stock options, excluding diversified mutual funds-Abbott (Any division) - 02/12/2025 |
| William Bommer, MD | Other Planning Committee Member | Nothing to disclose - 10/23/2024 |
| Scott Flinn, MD | Faculty | Nothing to disclose - 05/15/2024 |

**Agenda**

**[INSERT AGENDA HERE MANUALLY]**

**Acknowledgement of Commercial Support**

No commercial support has been received for this activity.